BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33747636)

  • 1. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
    Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
    Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
    He M; Zheng T; Zhang X; Peng Y; Jiang X; Huang Y; Tan B; Yang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1345-1355. PubMed ID: 34657171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Liao PF; Wang PY; Peng TR
    Curr Oncol; 2023 Nov; 30(11):9940-9952. PubMed ID: 37999142
    [No Abstract]   [Full Text] [Related]  

  • 4. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
    Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
    Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
    Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
    Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.
    Chen Y; Han H; Cheng J; Cheng Q; Zhu S; Zhan P; Liu H; Song Y; Lv T
    Cancer Immunol Immunother; 2024 Jun; 73(8):155. PubMed ID: 38834888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis.
    Monteiro FSM; Soares A; Mollica V; Leite CA; Carneiro APCD; Rizzo A; Bourlon MT; Sasse AD; Santoni M; Gupta S; Massari F
    Crit Rev Oncol Hematol; 2024 Apr; 196():104321. PubMed ID: 38460929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma.
    Nishiyama H; Yonese J; Kawahara T; Matsumoto R; Miyake H; Matsubara N; Uemura H; Eto M; Azuma H; Obara W; Terai A; Fukasawa S; Suekane S
    Mol Cancer Ther; 2024 Apr; 23(4):532-540. PubMed ID: 38060587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.
    Zou Y; Zou X; Zheng S; Tang H; Zhang L; Liu P; Xie X
    Ther Adv Med Oncol; 2020; 12():1758835920940928. PubMed ID: 32874208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
    Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
    Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis.
    Zhang X; Wu M; Chen J; Zheng K; Du H; Li B; Gu Y; Jiang J
    Heliyon; 2024 May; 10(10):e30809. PubMed ID: 38774326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
    Chen H; Feng Y; Zhou Y; Tao Y; Tang L; Shi Y
    Cancer Immunol Immunother; 2022 Dec; 71(12):3071-3085. PubMed ID: 35648238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis.
    Hong X; Zhang Y; Chi Z; Xu Q; Lin W; Huang Y; Lin T; Zhang Y
    Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e20-e30. PubMed ID: 37993317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis.
    Yoon SB; Woo SM; Chun JW; Kim DU; Kim J; Park JK; So H; Chung MJ; Cho IR; Heo J
    Front Immunol; 2024; 15():1321813. PubMed ID: 38605964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line immunotherapy efficacy in advanced squamous non-small cell lung cancer with PD-L1 expression ≥50%: a network meta-analysis of randomized controlled trials.
    Chen W; Liu H; Li Y; Xue W; Fan S; Sun J; Liu S; Liu Y; Zhang L
    Front Oncol; 2024; 14():1365255. PubMed ID: 38725635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Febriyanto T; Muhammad F; Wijaya W; Oey O; Simadibrata DM
    Urol Oncol; 2024 May; 42(5):160.e11-160.e23. PubMed ID: 38101990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.
    Wang Y; Sun Y; Lu F; Zhao X; Nie Z; Zhu F; He B
    Clin Transl Oncol; 2024 Jul; 26(7):1725-1737. PubMed ID: 38587602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
    Kim JH; Han KH; Park EY; Kim ET; Kim EJ; Tan DSP; Lee JY; Park SY; Fotopoulou C; Lim MC
    Gynecol Oncol; 2024 May; 187():85-91. PubMed ID: 38735144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
    Chen Y; Liu X; Hu Y; Xia L
    Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Maoxi Z; Jinmin X; Xiaozhu Z; Yubing Y; Yuxi Z
    J Oncol; 2021; 2021():3048974. PubMed ID: 34567113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.